Your browser doesn't support javascript.
loading
Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.
Zago, Elena; Galluzzo, Antonio; Pradella, Silvia; Antonuzzo, Lorenzo; Maggi, Mario; Petrone, Luisa; Sparano, Clotilde.
Afiliación
  • Zago E; Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
  • Galluzzo A; Department of Radiology, Careggi University Hospital, Florence, Italy.
  • Pradella S; Department of Radiology, Careggi University Hospital, Florence, Italy.
  • Antonuzzo L; Clinical Oncology Unit, Department of Experimental & Clinical Medicine, University of Florence, Florence, Italy.
  • Maggi M; Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
  • Petrone L; Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy. luisa.petrone@unifi.it.
  • Sparano C; Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Endocrine ; 83(1): 26-40, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37851242
PURPOSE: Cabozantinib is an oral multi-tyrosine kinase inhibitor (TKI) that has been approved in Europe for advanced renal cell carcinoma, hepatocellular carcinoma, locally advanced and metastatic medullary thyroid carcinoma (MTC) and radioiodine-refractory differentiated thyroid cancer. Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous malignant neuroendocrine tumour that usually presents in sun-exposed skin areas of immunosuppressed patients. Conflicting data exist about cabozantinib for MCC and this TKI is currently under investigation in several onco-endocrine frameworks. METHODS: We herein report a case of an 83-year-old man who was diagnosed with MCC during the treatment of an advanced metastatic MTC. The diagnosis of MCC was established based on clinical, histopathologic evaluation and immunohistochemistry. A systematic review of the literature on cabozantinib use for advanced endocrine and neuroendocrine tumours has been performed. RESULTS: The patient was initially treated with surgery and adjuvant radiotherapy. Cabozantinib was therefore started to control both MTC and MCC. After 24 months, no sign of local or metastatic MCC relapse was evidenced. CONCLUSION: Promising data on cabozantinib treatment for endocrine and neuroendocrine neoplasms is recently emerging in the literature. In our clinical case, we reported that, besides the good response for the MTC, cabozantinib also seems to effectively control metastatic MCC, along with efficient surgery and adjuvant radiotherapy. Further investigations are needed to determine the efficacy and safety of cabozantinib in MCC patients and in off-label endocrine tumours.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Neoplasias de la Tiroides / Carcinoma Neuroendocrino / Anilidas Tipo de estudio: Systematic_reviews Límite: Aged80 / Humans / Male Idioma: En Revista: Endocrine Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Neoplasias de la Tiroides / Carcinoma Neuroendocrino / Anilidas Tipo de estudio: Systematic_reviews Límite: Aged80 / Humans / Male Idioma: En Revista: Endocrine Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos